Therefore, the GALNT14-rs62139523 “A/G” genotype emerges as a potential biomarker for predicting outcomes in stage II and III colon cancer patients undergoing curative surgery followed by 5-FU-based adjuvant chemotherapy. Here, GALNT14 is linked to colonic neoplasm.